{"id":95025,"title":"Genedrive® MT-RNR1 ID Kit Product – Video","publisher":"Share Talk","author":"sharetalk","published":"2022-03-25T12:58:52+00:00","modified":"2022-03-25T13:05:10+00:00","canonical_url":"https://www.share-talk.com/genedrive-mt-rnr1-id-kit-product-video/","markdown_url":"https://www.share-talk.com/genedrive-mt-rnr1-id-kit-product-video.md","json_url":"https://www.share-talk.com/genedrive-mt-rnr1-id-kit-product-video.json","category":"Exclusive Interviews","categories":["Exclusive Interviews","Healthcare","Pharmaceutical"],"tags":["Antibiotic","biological","chemistry","coronavirus","COVID-19","COVID19","David Budd","diagnostics","GDR","Genedrive","Genedrive Kit","Genedrive PLC","hospital","infectious diseases","lab testing","Manchester","Matthew Fowler","molecular","SARS-COV-2","Share Talk"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2023/11/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.jpeg?fit=1231%2C615&quality=89&ssl=1","format":"news","language":"en-GB","content":"**World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss​​**\n\nPrevention – reduces the likelihood of aminoglycoside-induced hearing loss\n\nRapid results – point-of-care genetic test yields results in 30 minutes\n\nSimple to use – by healthcare professionals with minimal training\n\n**An in vitro diagnostic (IVD) molecular assay for use in human buccal cells**\n\nThe Genedrive® MT-RNR1 ID Kit used in conjunction with the Genedrive® System provides an automated result of an individual’s MT-RNR1 m.1555 variant status to inform the clinician ahead of antibiotic treatment decisions. ​\n\nThe Genedrive® MT-RNR1 ID Kit is intended to be used by healthcare professionals within a near patient setting.​\n\nThe Genedrive® System is a compact benchtop system that provides rapid nucleic amplification, detection and result reporting without the need for data interpretation\n\n- Reduces the likelihood of aminoglycoside induced hearing loss\n\n- Provides a clear patient benefit by informing the clinician ahead of prescription\n\n- Rapid genetic screening prior to aminoglycoside treatment\n\nIndividuals with the MT-RNR1 m.1555A>G variant develop profound irreversible hearing loss if exposed to aminoglycoside – population-based studies estimate prevalence of 1:500 (0.2%)\n\n- Single use, cost effective test for use by healthcare professionals with minimal training\n\n- Easy adoption into existing neonatal admissions process to inform clinicians ahead of antibiotic treatment decisions\n\n- Non-invasive test using buccal swabs from the inner cheek\n\n[First NHS Deployments of Genedrive System for AIHL](https://www.share-talk.com/genedrive-plc-aimgdr-first-nhs-deployments-of-genedrive-system-for-aihl/#gs.ukdaze)\n\n![](https://www.share-talk.com/wp-content/uploads/2022/03/Product-Google-Chrome-2022-03-25-at-12.33.03-PM-300x105.jpeg)\n\n \n\n \n\n![](https://www.share-talk.com/wp-content/uploads/2022/03/Product-Google-Chrome-2022-03-25-at-12.33.50-PM-300x86.jpeg)"}